"ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer patients for whom immunotherapy is not an option.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

Detailed price information for Daiichi Sankyo Ltd (DSKYF) from The Globe and Mail including charting and trades.

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a ...

The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed with ...